3β-<(tert-butyloxycarbonyl)amino>-9-benzyl-9-azabicyclo<3.3.1>nonane | 153431-10-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3β-<(tert-butyloxycarbonyl)amino>-9-benzyl-9-azabicyclo<3.3.1>nonane
• 英文别名: tert-butyl ((1R,3s,5S)-9-benzyl-9-azabicyclo[3.3.1]nonan-3-yl)carbamate；tert-butyl 9-benzyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamate；3β-[(tert-butyloxycarbonyl)amino]-9-benzyl-9-azabicyclo[3.3.1]nonane
• CAS: 153431-10-8
• 化学式: C₂₀H₃₀N₂O₂
• 分子量: 330.47
• InChiKey: JSCHDMDXTYLNBN-NNZMDNLPSA-N

物化性质

• 沸点：
  445.0±34.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  24.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  41.57
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  3β-<(tert-butyloxycarbonyl)amino>-9-benzyl-9-azabicyclo<3.3.1>nonane 在 三氟乙酸 作用下， 反应 2.0h， 以98%的产率得到9-benzyl-9-azabicyclo[3.3.1]nonan-3-amine
  参考文献：
  名称：

  Fluorine-18 labeled benzamides for studying the dopamine D2 receptor with positron emission tomography

  摘要：

  Two series of (N-benzylpiperidin-4-yl)- and (9-azabicyclo[3.3.1]nonan-3beta-yl)benzamides were prepared, and in vitro binding assays were used to measure the affinity of these compounds for dopamine D2, dopamine D3, serotonin 5-HT2, and alpha2-adrenergic receptors. The results of these studies indicated compounds 23, 26b, and 34 have the selectivity needed for in vivo studies of the D2 (and possibly D3) receptors. F-18-Labeled analogues of 23, 26b and 34 were prepared by N-alkylation of the corresponding desbenzyl precursors with [F-18]-4-fluorobenzyl iodide. Preliminary in vivo studies demonstrated that [F-18]-23 and [F-18]-26b are suitable candidates for further evaluation in positron emission tomography imaging studies. The slow rate of washout of [F-18]-34 from nondopaminergic regions and its comparatively high lipophilicity indicates that this compound may not be suitable for imaging studies because of a high level of nonspecific binding.

  DOI：

  10.1021/jm00075a028
• 作为产物：
  描述：

  9-苄基-9-氮杂双环[3.3.1]壬烷-3-酮 在 盐酸 、 锂硼氢 作用下， 生成 3β-<(tert-butyloxycarbonyl)amino>-9-benzyl-9-azabicyclo<3.3.1>nonane
  参考文献：
  名称：

  Yang, Biao; Johnston Jr., Douglas E.; Luedtke, Robert R., Medicinal Chemistry Research, 1998, vol. 8, # 3, p. 115 - 131

  摘要：

  DOI：

文献信息

• [EN] PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES<br/>[FR] INHIBITEURS DE JAK À BASE DE PYRIMIDINE POUR LE TRAITEMENT DE MALADIES DE LA PEAU
  申请人：THERAVANCE BIOPHARMA R&D IP LLC

  公开号：WO2020219640A1

  公开（公告）日：2020-10-29

  The invention provides compounds of formula (I): or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat inflammatory and autoimmune skin diseases.

  该发明提供了式(I)的化合物或其药用可接受盐，这些化合物是Janus激酶的抑制剂。该发明还提供了包含这些化合物的药物组合物，以及使用这些化合物治疗炎症性和自身免疫性皮肤疾病的方法。
• [EN] ESTER AND CARBONATE PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS<br/>[FR] COMPOSÉS D'ESTER ET DE CARBONATE DE PYRIMIDINE EN TANT QU'INHIBITEURS DE KINASE JAK
  申请人：THERAVANCE BIOPHARMA R&D IP LLC

  公开号：WO2020219639A1

  公开（公告）日：2020-10-29

  The invention provides compounds of formula (I): (I) or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases and release an active metabolite in vivo. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat inflammatory skin diseases and other diseases.

  该发明提供了式(I)的化合物或其药用盐，这些化合物是Janus激酶的抑制剂，并在体内释放活性代谢物。该发明还提供了包含这些化合物的药物组合物，以及使用这些化合物治疗炎症性皮肤病和其他疾病的方法。
• PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR
  申请人：THERAVANCE BIOPHARMA R&D IP, LLC

  公开号：US20190127364A1

  公开（公告）日：2019-05-02

  The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.

  该发明提供了化合物的结构式(I)：或其药用盐，该化合物是JAK激酶的抑制剂。该发明还提供包含此类化合物的药物组合物、晶体形式、使用该化合物治疗炎症性皮肤病和其他疾病的方法，以及用于制备该化合物的工艺和中间体。
• Synthesis of analogs of the radiation mitigator JP4-039 and visualization of BODIPY derivatives in mitochondria
  作者：Marie-Céline Frantz、Erin M. Skoda、Joshua R. Sacher、Michael W. Epperly、Julie P. Goff、Joel S. Greenberger、Peter Wipf

  DOI：10.1039/c3ob40489g

  日期：——

  JP4-039 is a lead structure in a series of nitroxide conjugates that are capable of accumulating in mitochondria and scavenging reactive oxygen species (ROS). To explore structure–activity relationships (SAR), new analogs with variable nitroxide moieties were prepared. Furthermore, fluorophore-tagged analogs were synthesized and provided the opportunity for visualization in mitochondria. All analogs were tested for radioprotective and radiomitigative effects in 32Dcl3 cells.

  JP4-039 是一系列硝基氧化物共轭物的先导结构，能够在线粒体中积累并清除活性氧（ROS）。为了探索结构-活性关系（SAR），我们制备了具有可变亚硝基的新类似物。此外，还合成了荧光团标记的类似物，为线粒体中的可视化提供了机会。所有类似物都在 32Dcl3 细胞中进行了辐射防护和辐射诱变效应测试。
• Pyrimidine compound as JAK kinase inhibitor
  申请人：THERAVANCE BIOPHARMA R&D IP, LLC

  公开号：US10308646B2

  公开（公告）日：2019-06-04

  The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.

  本发明提供了一种式 (I) 的化合物： 或其药学上可接受的盐，是一种 JAK 激酶抑制剂。本发明还提供了包含这种化合物的药物组合物、结晶形式、使用这种化合物治疗炎症性皮肤病和其他疾病的方法，以及制备这种化合物的有用工艺和中间体。